Image

Speech of Kids After Neonatal Encephalopathy

Speech of Kids After Neonatal Encephalopathy

Recruiting
7 years and younger
All
Phase N/A

Powered by AI

Overview

The goal of this ambispective cohort study is to reveal the early indicators of delayed language development in children born with hypoxic-ischemic encephalopathy (HIE).

We will examine the prognostic accuracy of different biomarkers, with a special focus on the ADC values of the corpus callosum.

The main questions it aims to answer are:

  1. To what extent does hypoxic-ischemic encephalopathy (HIE) in infancy affect intellectual development (IQ), receptive and expressive language abilities at different levels of the language system, and memory capacities related to language development?
  2. What is the relationship between early biomarkers of brain injury-such as blood gas levels, lactate, aEEG, and MRI findings (Weeke scoring system, ADC values of the corpus callosum)-and long-term cognitive developmental outcomes?
  3. What is the incidence of autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) in this high-risk population of infants with HIE?
  4. Is there an association between the Weeke Total Score and long-term language developmental outcomes?
  5. Can restricted diffusion (ADC values) of the splenium of the corpus callosum serve as an early neuroradiological marker of developmental language disorder (DLD)?

Our participants are children born between 2017 and 2023 with moderate to severe HIE, treated with therapeutic hypothermia at Semmelwies University Children's Hospital. During their first days of life, several neonatal measurements were taken (blood gas markers, aEEG etc.), and at day 4-5, they had an MRI scan of their brain. The MRI scans will be reanalyzed, using the Weeke MRI scoring system. These children underwent a neurodevelopmental follow-up at the age of 2 years and currently, they will have another follow-up at the age of 4-7 years.

Description

This ambispective, single-center cohort study will investigate the cognitive and language development of children aged 4-7 years who were previously treated for hypoxic-ischemic encephalopathy (HIE) and underwent standardized neurodevelopmental assessment at two years of age. In addition to developmental outcomes, the study will incorporate clinical, laboratory, and imaging data collected during the neonatal period. All available neonatal MRI scans will be re-evaluated according to predefined criteria. Recruitment and data collection will take place from April 1, 2025, to December 31, 2026. The study population will include children whose parents provided consent for follow-up assessments at the two-year evaluation.

Phase 1.: Blood gas values like pH, base deficit, PCO2, PO2, HCO3, and lactate were registered. aEEG cerebral activity was recorded using continuous single channel (biparietal, P3-P4) aEEG monitoring. It started before 6 hours of age.

Phase 2. : MRI scans was perfomed between the 4-5th day of postnatal age. The MRI scans will be reanalyzed, using the Weeke MRI scoring system.

Phase 3. : At the age of 2 years participating children underwent neurodevelopemntal follow-up, where the Bayley Scales of Infant and Toddler Development, Second Edition (Bayley-II) was used. It is a standardized tool for assessing the developmental functioning of children from 1 to 42 months of age. The test provides both a Mental Development Index (MDI) and a Psychomotor Development Index (PDI) to summarize performance in key areas.

Phase 4.: At the age of 4-7 years the children will undergo their second neurodevelopmental assessment. Within this assessment we will administer the following:

Wechsler Preschool and Primary Scale of Intelligence - Fourth Edition (WPPSI-IV), which assesses Full-Scale IQ, Verbal IQ, and Performance IQ in children aged 4 years to 7 years.

Complex Test of Spoken Language Skills (KOBAK), the first comprehensive, standardized language assessment developed for Hungarian-speaking children. The KOBAK comprises 16 subtests evaluating expressive and receptive language functions across multiple domains (phonology, lexical semantics, morphology, syntax, and pragmatics), as well as speech motor functions and verbal working memory. The test enables evidence-based differentiation of average, above-average, and below-average language abilities; provides a detailed language profile; supports the assessment of school readiness; and facilitates screening, diagnosis, differential diagnosis, and longitudinal monitoring of language development.

As part of the neurodevelopmental assessment, parents will complete several questionnaires:

Socioeconomic Questionnaire (assessing parental education, income, and related variables) Jaworsky Questionnaire Social Communication Questionnaire (SCQ) ScreenQ ADHD Rating Scale Strengths and Difficulties Questionnaire (SDQ)

Eligibility

Children born between 2017 and 2023 with moderate to severe HIE, treated with therapeutic hypothermia at Semmelweis University Children's Hospital.

Inclusion criteria

  1. Born at ≥ 35th week of gestation
  2. Attended follow-up examinations at two years of age
  3. Has parental informed consent

Exclusion criteria

  1. Hearing loss
  2. Multilingual language environment
  3. Congenital abnormalities
  4. Metabolic disease
  5. Sudden unexpected postnatal collapse
  6. Brain injury not caused by HIE
  7. Severe motor impairment defined as a score <70 on the psychomotor development index (PDI) at 2 years of age

Study details
    HIE - Hypoxic - Ischemic Encephalopathy
    Language Delay
    Autism
    ADHD - Attention Deficit Disorder With Hyperactivity
    Specific Language Impairment
    Intellectual Developmental Disorder

NCT07136636

Semmelweis University

15 October 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.